Literature DB >> 22505544

A new dot immunoassay for simultaneous detection of celiac specific antibodies and IgA-deficiency.

Karsten Conrad1, Dirk Roggenbuck, Annelore Ittenson, Dirk Reinhold, Thomas Buettner, Martin W Laass.   

Abstract

BACKGROUND: This study investigated whether a dot immunoassay (DIA) can provide simultaneous detection of anti-tissue transglutaminase (tTG), anti-deamidated gliadin (DG) and total IgA antibodies, as required in the work-up of celiac disease (CD) patients.
METHODS: Celiac disease patients (n=111) consecutively diagnosed from 2001 to 2011 at the Children's Hospital and Institute of Immunology (Technical University Dresden) were tested for anti-tTG, anti-DG and total IgA by enzyme-linked immunosorbent assay (ELISA) and DIA retrospectively. Blood donors (n=45) and non-CD individuals with low IgA serum levels (n=8) were included as controls. Antibodies to endomysial antigens (EmA) were assessed by indirect immunofluorescence (IIF).
RESULTS: Four (3.6%) of 111 CD patients demonstrated an IgA deficiency with total IgA below 50 mg/L by ELISA. Total IgA of the 107 IgA-non-deficient CD patients varied from 70 to 6000 mg/L. All four IgA-deficient CD patients were detected by a reduced reaction control of DIA and demonstrated positive anti-tTG or anti-DG IgG by DIA or ELISA. Detection of anti-tTG and anti-DG by DIA and ELISA showed a very good agreement (IgA: κ=0.972, 0.856, respectively; IgG: 0.921, 0.895, respectively).
CONCLUSIONS: Immunodot assay is a reliable and easy-to-use technique for the detection of IgA-deficient CD patients. Simultaneous assessment of anti-tTG and anti-DG IgA antibodies, and IgA deficiency by DIA can improve the efficacy of CD serology.

Entities:  

Mesh:

Year:  2012        PMID: 22505544     DOI: 10.1515/cclm.2011.760

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  ACG clinical guidelines: diagnosis and management of celiac disease.

Authors:  Alberto Rubio-Tapia; Ivor D Hill; Ciarán P Kelly; Audrey H Calderwood; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2013-04-23       Impact factor: 10.864

2.  Loss and Gain of Tolerance to Pancreatic Glycoprotein 2 in Celiac Disease.

Authors:  Martin W Laass; Nadja Röber; Ursula Range; Lydia Noß; Dirk Roggenbuck; Karsten Conrad
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 3.  "New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome.

Authors:  Roberta Misasi; Antonella Capozzi; Agostina Longo; Serena Recalchi; Emanuela Lococo; Cristiano Alessandri; Fabrizio Conti; Guido Valesini; Maurizio Sorice
Journal:  J Immunol Res       Date:  2015-03-19       Impact factor: 4.818

Review 4.  New platform technology for comprehensive serological diagnostics of autoimmune diseases.

Authors:  Annika Willitzki; Rico Hiemann; Vanessa Peters; Ulrich Sack; Peter Schierack; Stefan Rödiger; Ursula Anderer; Karsten Conrad; Dimitrios P Bogdanos; Dirk Reinhold; Dirk Roggenbuck
Journal:  Clin Dev Immunol       Date:  2012-12-19

5.  Serological assessment for celiac disease in IgA deficient adults.

Authors:  Ning Wang; Lennart Truedsson; Kerstin Elvin; Bengt A Andersson; Johan Rönnelid; Lucia Mincheva-Nilsson; Annica Lindkvist; Jonas F Ludvigsson; Lennart Hammarström; Charlotte Dahle
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

6.  Simultaneous detection of celiac disease-specific IgA antibodies and total IgA.

Authors:  Kai Grossmann; Nadja Röber; Rico Hiemann; Stefan Rödiger; Peter Schierack; Dirk Reinhold; Martin W Laass; Karsten Conrad; Dirk Roggenbuck
Journal:  Auto Immun Highlights       Date:  2016-01-30

Review 7.  Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.

Authors:  Mandy Sowa; Rico Hiemann; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.